These DCs are isolated from the patient, pulsed with tumor-associated antigens such as gp100 or tyrosinase peptides, or transfected with tumor-derived RNA through electroporation, and subsequently reinfused to induce a tumor-specific T cell response. The gene discussed is PMEL; the disease is neoplasm.